In vitro DNA amplification followed by oligonucleotide dot blot analysis were used to study RAS gene mutations in acute myeloid leukemia (AML). Fifty-two presentation AML DNAs were screened for mutations in codons 12, 13, and 61 of NRAS and in codons 12 and 61 of KRAS and HRAS. Fourteen (27%) contained mutations-all in NRAS and predominantly in codon 12. The most common amino acid substitution identified was of glycine by aspartic acid at codon 12 (7/18), with a G -* A transition being the most common base change (11/18). No particular correlation was observed between disease subtype and the incidence or type of NRAS mutation. In DNA samples from four patients, 2 NRAS mutations were found to coexist. NIH 3T3 focus-formation assays revealed that in each case the mutations were present in different NRAS alleles. We also report the absence of a mutated RAS gene in relapse DNAs of four patients in which a RAS oncogene had been detected at presentation. These observations suggest that RAS mutations arise as part of the evolution of neoplastic transformation.
Mutations leading to the activation of the transforming potential of cellular RAS genes have been implicated in the development of many human malignancies of diverse origin. Normal mammalian cells contain three closely related ras protooncogenes, HRAS, KRAS, and NRAS, encoding 21-kDa proteins that bind guanine nucleotides, possess intrinsic GTPase activity, and are located at the inner surface of the plasma membrane (1) . Activating mutations of RAS genes that have been detected in vivo occur in codons 12, 13, and 61 (2) (3) (4) . These codons fall within two regions of homology, which appear to form important components of the GTPbinding site (5, 6) . In vitro mutagenesis studies on HRAS have revealed additional sites at which amino acid substitutions can activate the transforming potential of p21: in the region neighboring codon 61, the substitution of threonine for alanine at position 59, and the mutation of glutamic acid to lysine at position 63 (7) . Substitutions at positions 116 (asparagine) and 119 (aspartic acid), two residues that determine the guanine specificity of nucleotide binding (5, 6) , also increase the transforming capacity of p21 (8, 9) . Mutations at codons 59, 63, 116, and 119 have yet to be found as activating lesions in vivo.
Induction of tumors in experimental animals by chemical carcinogenesis leads in some systems to reproducible activation of the same RAS oncogene, often with the same mutation (10) (11) (12) (13) . In some types of human cancer, there also appears to be a distinct bias for transforming mutations affecting a particular member of the RAS family. For example, only activation of HRAS has been reported in human bladder and urinary carcinomas (ref. 14; K. Visvanathan and I. C. Summerhayes, personal communication); mutations in KRAS are most common in lung and colon carcinomas (15) (16) (17) (18) (19) , whilst activated NRAS predominates in hematopoietic malignancy (3, 20, 21) .
Recently, Saiki and colleagues (22) have used synthetic oligonucleotide probes to identify point mutations and allelic sequence variation in DNA enzymatically amplified by the polymerase chain reaction (PCR) technique (23) . In the present study, we have applied this approach to the detection of RAS gene mutations in acute myeloid leukemia (AML) DNAs. With this in vitro amplification technique, specific regions of DNA can be amplified >105-fold after 25 cycles of in vitro DNA synthesis. These highly amplified sequences are then a suitable substrate for oligonucleotide probing experiments using probes of moderate specific activity and short autoradiographic exposures.
MATERIALS AND METHODS Materials. DNA was extracted from leukapheresed blood taken at the time of initial diagnosis (prior to chemotherapy) and cryopreserved. Eight of the 52 patients screened were followed up as the disease progressed and samples were obtained during remission and/or relapse states.
Synthetic Oligonucleotides. The oligomers were synthesized by the solid-phase triester method. The oligonucleotide probes were 5'-end-labeled by phosphorylation with [-32P]ATP (Amersham; specific activity, >5000 Ci/mmol; 1 Ci = 37 GBq) and T4 polynucleotide kinase (Amersham), and they were routinely purified by spin dialysis over 1-ml Bio-Gel P4 Fine (Bio-Rad) columns. The procedure gave probes with specific activities of =4.0 pCi/pmol. Where probes of identical specific activity were required, the kinased oligomers were purified over a 10o polyacrylamide/7 M urea gel, which allows separation of the labeled 20-mer from its unlabeled precursor (3, 24) .
PCR and Oligonucleotide Probe Hybridization. Genomic DNA (1 pg) was subjected to 25 cycles of PCR amplification as described (22) . GnT n = A,C,T N13wt GGA GCA GGT GGT GTT GGG AA N13 pl nGT n = A,C,T N13 p2
GnT n = A,C,T N61wt ACA GCT GGA CAA GAA GAG TA N61 pl nAA n = A,G N61 p2
CnA n = C,G,T N61 p3
CAn n = C,T N59 Thr CTG GAT ACA ACT GGA CAA GA N63 Lys GGA CAA GAA AAG TAC AGT GC wt, Wild type.
solution (1 x Denhardt's solution = 0.02% Ficoll/0.02% polyvinylpyrrolidone/0.02% bovine serum albumin). Approximately 1 pmol of probe (2 x 106 cpm/ml) was then added and hybridization was continued at the same temperature for 1 hr. Filters were washed twice in 2 x SSPE (1 x SSPE = 10 mM sodium phosphate, pH 7.2/0.18 M NaCl/1 mM EDTA)/0.1% NaDodSO4 for 10 min at room temperature. Then, the filters were rinsed in 3 M tetramethylammonium chloride hybridization buffer minus carrier DNA and Denhardt's solution, and washed in this solution for 30-60 min at 60°C. Finally, the filters were autoradiographed at -70°C (Kodak XAR) for 1-12 hr. Quantitative analyses of dot blots were performed by densitometry of preflashed x-ray film (25) . DNA Transfection. NIH 3T3 focus-formation assays were carried out as described (26) .
RESULTS
NRAS Mutations in Presentation AML DNAs. DNA samples from 52 patients with AML were screened for the presence of N-, K-, and HRAS gene mutations using synthetic oligonucleotide probes and an in vitro amplification step. Since the activating mutations so far identified in vivo are at or near the 12th or 61st codon, amplified DNAs were analyzed with a set of oligomers each designed to be complementary to a different point mutation within sequences around the two regions (Table 1 ). This approach allows for the identification of all possible single base-pair substitutions in these codons because a fully matched hybrid between the oligomer and genomic DNA is thermally more stable than a single base-pair mismatch hybrid.
The sensitivity of this approach is dramatically increased by the introduction of an enzymatic amplification step (22, 23, 27) . In the PCR analysis of each RAS gene, two sets of 20-base oligonucleotide primers are used, which hybridize to opposite strands of the genomic DNA flanking the target sequence around either codons 12/13 or 61. After repeated DNA from the HT1080 cell line (heterozygous for N61 lysine) was diluted with normal human placental DNA, such that a series of samples was amplified, representing from 100% to 0.1% of the cells from which DNA was extracted containing the mutant allele. Samples were spotted out in triplicate and hybridized with the N61 wild-type (wt) and N61 lysine oligomers.
cycles of denaturation, annealing, and chain elongation, DNA target sequences of 112-115 bases are generated (Fig.   1 ).
Since in AML the numbers of circulating blasts vary considerably, the sensitivity of our standard PCR/oligonucleotide protocol was assessed. DNA from cell lines carrying a known RAS mutation (HT1080, heterozygous for N61 lysine; and EJ, homozygous for H12 valine) was diluted with normal human placental DNA, such that a series of samples was amplified, which represented from 100% to only 0.1% of the cells from which DNA was extracted containing the mutant allele. Similar results were obtained from both dilution series (Fig. 2) . Using our standard protocol it is possible to clearly identify a mutation present at only the 10% level. Below this, the signal approaches background.
Of the 52 initial presentation AML samples screened [FAB subtypes (French-American-British classification) Ml, M2, and M4], 14 contained RAS mutations ( Table 2 , Fig. 3 ). These mutations were all in NRAS and predominantly at codon 12. The most common amino acid substitution identified was aspartic acid for glycine (9/18). The most common base change was a G --A transition (11/18 DNAs, only 2 codon 13 mutations were detected (both aspartates). In two patients who had gone into remission after therapy, analysis of a peripheral blood sample taken during remission showed that the RAS gene mutation found at initial presentation (951/N12 serine, 43/N12 cysteine) was undetectable.
The presentation samples were also screened for threonine-59 and lysine-63 substitutions, two activating mutations that have been identified by in vitro mutagenesis studies (7) . No mutations at these sites were found in either NRAS or HRAS.
To determine the relative strength of mutant and normal RAS gene signals in relation to the percentage of peripheral blasts in the various samples, densitometry measurements were taken. These studies show that in some leukemic samples with a high proportion of blast cells, the mutant RAS gene appears to be present in only a fraction of the circulating leukemic blasts (e.g., AML-67, -71).
Presence of More Than One NRAS Mutation in Some AML DNAs. Amplified DNA samples from four AML patients (AML-10, -35, -67, and -96) formed stable hybrids with two different mutant-specific probes. These samples therefore appear to contain more than one mutation. To confirm these results, the original DNA samples were used in an NIH 3T3 transfection assay and a series of independently transformed foci was isolated. Analysis of these transfectant DNAs showed that different foci contained one or the other of these RAS gene mutations but never both (Fig. 4) . Thus, these DNAs contain two mutant RAS genes, but the mutations are not in the same allele of NRAS. Furthermore, in the case of mutations occurring simultaneously in codons 12 and 13 in the same leukemic genome, their very detection using this approach indicates that they cannot be present in the same allele, as this would obviously result in thermal instability of the DNA hybrid. Comparison of the strengths of the hybridization signals from these samples showed that in most cases the signals from the two mutant probes were similar. However, in one case, AML-35, the N12 aspartate mutation was considerably weaker than either the N13 aspartate or the normal NRAS signal (Fig. 3) . Such data argue that the leukemic sample contains different clones of cells bearing RAS mutations.
Absence of RAS Gene Mutations in Relapse DNAs from Patients Whose Presentation Sample Contained a Mutation. We screened for N-, K-, and HRAS mutations in samples from seven patients, who had relapsed after a period in remission ( Table 2, Fig. 3 ). In three cases (presentation/relapse pairs: 961/13, 318/788, and 908/948), no RAS mutation had been detected in the presentation samples and no mutation was identified on relapse. In a further four cases, RAS mutations had been detected in the presentation samples (one N12 Asp-126; two N12 Ser-921, -951; one N12 Cys-96; one N61 His-96). Strikingly, no RAS mutation could be identified in the relapse DNAs. Since AML is sometimes treated by bone marrow transplantation, the absence of a mutation in relapse could arise from leukemia in the donor marrow. However, in these cases, bone marrow transplantation had not been performed. To preclude the possibility of inadvertent confusion of clinical samples, the presentation/ relapse pairs were subjected to DNA fingerprinting (data not shown). This confirmed that they were derived from the same individual in each case.
DISCUSSION
We have used a sensitive technique based on enzymatic amplification of target DNA sequences followed by oligonucleotide dot blot analysis to study RAS gene mutations in human AML. This approach has the advantages that large numbers of samples can be screened, it is sensitive, and it allows detection of all possible single-base mutations at codons 12, 13, and 61. Fourteen of 52 (27%) presentation samples contained mutations of NRAS. This confirms our (and others) previous experience that mutations in NRAS are the most frequently found in AML and mutations in HRAS and KRAS occur but are less common (3, 28, 29 ). No (31, 32) . The results therefore argue that the bone marrow in remission did not contain cells bearing the RAS gene mutations. In these four cases, therefore, it is unlikely that the mutations of the RAS genes were the initiating event in leukemogenesis; otherwise, the relapse samples would be expected to bear the same mutation. Moreover, some leukemic samples appear to contain NRAS genes mutated at two different sites, and in some samples with a large fraction of leukemic blasts the hybridization signal from the mutant probe is much reduced relative to the wild-type signal. These observations also suggest that some mutations are arising after the initial transforming event and are part of the clonal evolution of the disease. The simultaneous presence of activated NRAS and KRAS oncogenes in the same tumor DNA has been reported elsewhere (19) . Such an interpretation of the time at which RAS gene mutations occur is at variance with the view derived from experimental tumor models in rodents (10) (11) (12) (13) 33) and from studies on human colon villous adenomas/carcinomas (18, 19) , which argues that RAS gene mutations are an early initiating event in tumorigenesis. Furthermore, Hirai and colleagues (34) and others (R. A. Padua, G. Carter, J. Gow, D. Hughes, C. J. F., F. M., and A. Jacobs, unpublished data) have shown the presence of NRAS gene mutations in bone marrow from patients with myelodysplasia, a condition that predisposes to acute myeloid leukemia. It therefore seems likely that RAS gene mutations can occur at a number of stages in transformation, either as initiating events and/or later as part of the evolution of neoplastic transformation.
